PAMS
ESPR

Pictet Asset Management (Switzerland)’s Esperion Therapeutics ESPR Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-191,547
Closed -$889K – 1614
2022
Q1 		$889K Hold
191,547
– – ﹤0.01% 1069
2021
Q4 		$958K Buy
191,547
+59,698
+45% +$478K ﹤0.01% 1087
2021
Q3 		$1.59M Buy
+131,849
New +$1.92M ﹤0.01% 1020

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ESPR Position: Q2 2022 in Review

Pictet Asset Management (Switzerland) sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 191,547 shares — an estimated $889K sold.

Pictet Asset Management (Switzerland) first reported a position in ESPR in Q3 2021 and held it in 3 quarters. The position peaked at $1.59M in Q3 2021. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

  • Pictet Asset Management (Switzerland) reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 191,547 Esperion Therapeutics shares in Q2 2022, an estimated $889K.
  • Pictet Asset Management (Switzerland) first reported a position in Esperion Therapeutics in Q3 2021 and held it in 3 quarters.
  • Pictet Asset Management (Switzerland)'s Esperion Therapeutics position peaked at $1.59M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2022, filed 9 Aug 2022.